60 research outputs found
Association between prostatic 18F-FDG uptake and lower urinary tract symptoms assessed by International Prostate Symptom Score
PURPOSEInflammation is known to induce prostatic growth and lower urinary tract symptoms (LUTS) progression in patients with benign prostatic hyperplasia (BPH), but clinical indicators for intraprostatic inflammation other than biopsy have not yet been established. While 2-deoxy- 2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is a useful tool for investigating inflammatory conditions, prostatic FDG uptake in patients with BPH has not been elucidated. Therefore, we evaluated the association between prostatic FDG uptake and LUTS.METHODSA total of 391 men in their 50s who underwent FDG PET/CT during health examinations were included. Mean and maximal prostatic standard uptake values (SUVs) on FDG PET/CT were measured. Prostatic volume, focal FDG uptake, and calcification were also evaluated. The International Prostate Symptom Score (IPSS) for LUTS was collected at baseline and follow- ups. The correlation between IPSS and other variables was analyzed.RESULTSThe mean age of the study participants was 51.7 years, and the mean follow-up interval was 39.7 months. The average of the mean and maximal SUV for prostatic FDG uptake was 1.8 and 2.6, respectively. The prostate volume was 18.5 cm3. The mean IPSS was 4.82 at baseline and 5.46 at follow-ups. Neither the mean SUV nor the maximal SUV of prostatic FDG uptake was correlated with IPSS at baseline or follow-ups. Conversely, prostate volume was associated with baseline IPSS and follow-up IPSS.CONCLUSIONProstatic FDG uptake did not show a significant association with IPSS on FDG PET/CT as well as at follow-ups. FDG uptake may not reflect prostatic growth in nonmalignant cases
Elevated red cell distribution width is associated with advanced fibrosis in NAFLD
Background/AimsThe red-blood-cell distribution width (RDW) is a newly recognized risk marker in patients with cardiovascular disease, but its role in nonalcoholic fatty liver disease (NAFLD) has not been well defined. The aim of the present study was to determine the association between RDW values and the level of fibrosis in NAFLD according to BARD and FIB-4 scores.MethodsThis study included 24,547 subjects who had been diagnosed with NAFLD based on abdominal ultrasonography and questionnaires about alcohol consumption. The degree of liver fibrosis was determined according to BARD and FIB-4 scores. The association between RDW values and the degree of fibrosis in NAFLD was analyzed retrospectively.ResultsAfter adjusting for age, hemoglobin level, mean corpuscular volume, history of hypertension, history of diabetes, and high-sensitivity C-reactive protein, the RDW values were 12.61Β±0.41% (meanΒ±SD), 12.70Β±0.70%, 12.77Β±0.62%, 12.87Β±0.82%, and 13.25Β±0.90% for those with BARD scores of 0, 1, 2, 3, and 4, respectively, and 12.71Β±0.72%, 12.79Β±0.66%, and 13.23Β±1.52% for those with FIB-4 scores of <1.30, 1.31-2.66, and β₯2.67, respectively (P<0.05). The prevalence of advanced fibrosis (BARD score of 24 and FIB-4 score of β₯1.3) increased with the RDW [BARD score: 51.1% in quartile 1 (Q1) vs. 63.6% in Q4; FIB-4 score: 6.9% in Q1 vs. 10.5% in Q4; P<0.001]. After adjustments, the odds ratio of having advanced fibrosis for those in Q4 compared to Q1 were 1.76 (95%CI=1.55-2.00, P<0.001) relative to BARD score and 1.69 (95%CI=1.52-1.98, P<0.001) relative to FIB-4 score.ConclusionsElevated RDW is independently associated with advanced fibrosis in NAFLD
Clinical Effectiveness of Urinary Human Chorionic Gonadotropin Related Protein (hCGRP) Quantification for Diagnosis of Ectopic Pregnancy
We detected pregnancy related new molecule, human chorionic gonadotropin related protein (hCGRP) in the urine of a pregnant women by using a monoclonal antibody against the human chorionic gonadotropin (hCG). This study examined the effectiveness of urinary hCGRP quantification in diagnosing ectopic pregnancy. This study included 40 normal pregnant women and 25 patients with ectopic pregnancy. Patients' serum and urinary intact whole hCG (i-hCG) and hCGRP concentrations were measured using sandwich ELISA and the ratio of hCGRP to i-hCG was calculated. Statistical analysis was performed using statistical package for social sciences (SPSS) 10.0. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the cut-off value to discriminate ectopic pregnancies from normal intrauterine pregnancies. Urinary hCGRP and hCGRP/i-hCG ratio in ectopic pregnancy group (14Β±6.6 ng/mL, 4.6Β±1.9%, respectively) were significantly lower than those of normal pregnancy group (149Β±10.2 ng/mL, 29.7Β±1.9%, respectively; p<0.001). Based on ROC curve analysis, a cut-off point of urinary hCGRP/i-hCG ratio <16.2% discriminated between ectopic pregnancy and normal pregnancy with a sensitivity, specificity, positive predictive value and negative predictive value of 92.0%, 90.0%, 32.6%, and 99.5%, respectively. Urinary hCGRP/i-hCG ratio measurement may be effective in diagnosing ectopic pregnancy
Effect of aging on expression of nitric oxide and inducible nitric oxide synthase in human gingival fibroblasts
μΉμ£Όμ§νμ μ§νμ΄ λμ΄μ μν΄ μν₯μ λ°λλ€λ μ¬μ€μ μλ €μ Έ μμΌλ λ
Ένμ λ°λ₯Έ μΉμ£Όμ‘°μ§ μΈν¬μ κΈ°λ₯μ μΈ λ³νμ κ΄ν μ¬μ€μ λ§μ΄ μλ €μ Έ μμ§ μλ€. λ
Ένμ λ°λ₯Έ μΈν¬μ λ
Ένκ° μΉμ£Όμ§νμ μ§νμ μ΄λ ν μ¬ν₯μ λΌμΉλκ°λ₯Ό μλ κ²μ μ€μνλ€. μΌμ¦ μνμμ nitric oxide (NO)λ μ‘°μ§ νκ΄΄μ κ΄μ¬νλ μΈμλ‘ μμ©νμ¬ μΉμ£Όμ§νμ μ§νμ κ΄μ¬νλ κ²μΌλ‘ μλ €μ Έ μλ€. λ°λΌμ μ΄ μ°κ΅¬λ μ¬λμ μΉμμμ λ°°μλ μΉμμ¬μ μμΈν¬λ₯Ό μ΄μ©νμ¬ μΈν¬μ λ
Ένμ λ°λ₯Έ NOμ μ΄μ ν©μ±ν¨μμΈ inducible nitric oxide synthase (iNOS)μ λ°νμ μμλ΄μΌλ‘μ¨ μΈν¬μ λ
Ένκ° μΉμ£Όμ§νμ μ§νμ λΌμΉλ μν₯μ λν΄ μμλ³΄κ³ μ νμλ€. 10μΈμ νμμ 55μΈμ νμμμ κ°κ° μ±μ·¨ν μΉμμμ λ°°μλ μΈν¬μ 10μΈμ νμμμ μ±μ·¨ν μΈν¬λ₯Ό κ³μμ μΈ κ³λλ°°μμ ν΅ν΄ μ»μ μ€νμ€ μ λ
Ένλ μΈν¬λ₯Ό ν¬ν¨νμ¬ μ΄ 3 μ’
λ₯μ μΉμμ¬μ μΈν¬λ₯Ό μ€νμ μ΄μ©νμλ€. Hot phenol-water extractionμ ν΅ν΄ μΆμΆλ Porphyromonas, gingivalis ATCC 33277 lipopolysaccharide (LPS)μ μ¬μ‘°ν© λ₯Ό μΈν¬μ μ μ©μμΌ Griess assayλ₯Ό ν΅ν΄ 쑰건νλ λ°°μ§μμ NOλ₯Ό μΈ‘μ νμλ€. 20μΈμ 55μΈμ νμμμ μ±μ·¨λ μΉμ μ‘°μ§κ³Ό μ΄ 3 μ’
λ₯μ λ°°μλ μΈν¬μ NOS-II ν체λ₯Ό μ μ©μμΌ iNOS λ¨λ°±μ§ λ°νμ κ΄μ°°νμλ€. Total RNAλ₯Ό μΆμΆνμ¬ RT-PCRλ₯Ό ν΅ν΄ iNOS mRNAμ λ°νμ λΆμνμλ€. μΉμμ¬μ μμΈν¬μμ NOλ μλ°μ μΌλ‘ λ°μλμκ³ , μ΄λ¬ν λ°νμ μ μ μΈν¬λ³΄λ€ λ
Ένλ μΈν¬μμ κ°νμλ€. P, gingivalis LPSμ μ μ‘°ν© λ μΉμμ¬μ μμΈν¬μμ NOμ λ°νμ μ¦κ°μμΌ°κ³ , μ΄λ¬ν λ°νμ μ μ μΈν¬λ³΄λ€ λ
Ένλ μΈν¬μμ κ°νμλ€. λ©΄μμ‘°μ§νν μΌμμμ iNOS λ¨λ°±μ§μ μ μ μ¬λκ³Ό λ
Ένλ μ¬λμ μΉμ μ‘°μ§ λͺ¨λμμ μΉμμ¬μ μμΈν¬μ μνΌμ κΈ°μ μΈ΅ μΈν¬μ μΌμ¦μΈν¬μμ λ°νλμμΌλ λ
Ένμ λ°λ₯Έ λ°νμ μ°¨μ΄λ₯Ό ꡬλ³ν μλ μμλ€. μΈν¬μ λ©΄μμΌμμμ iNOS λ¨λ°±μ§μ λ
Ένλ μΈν¬μμ κ°νκ² λ°νλμκ³ μ΄λ¬ν λ°νμ LPSμ μ μν΄ κ°νλμλ€. LPSμ μ μ‘°κ±΄μ΄ μ£Όμ΄μ§μ§ μμ μνμμ iNOS mRNAλ μ μ μΈν¬μμλ³΄λ€ λ
Ένλ μΈν¬μμ κ°νκ² λ°νλμλ€. μ΄λ¬ν κ²°κ³Όλ₯Ό ν΅ν΄ μΈν¬μ λ
Ένκ° NOμ iNOS λ°νμ μ¦κ°μν΄μΌλ‘μ μΉμ£Όμ§νμ μ§νμ μν₯μ λΌμΉ μ μμμ μμ¬νμλ€.This study was supported by a grant of the Korea Health 21 R&D project, Ministy of Health & Welfare, Republix of Korea(03-PJ1-CH08-001)
λ Ένκ° μ¬λ μΉμμ¬μ μμΈν¬μ nitric oxideμ inducible nitric oxide synthase λ°νμ λΌμΉλ μν₯
μΉμ£Όμ§νμ μ§νμ΄ λμ΄μ μν΄ μν₯μ λ°λλ€λ μ¬μ€μ μλ €μ Έ μμΌλ λ
Ένμ λ°λ₯Έ μΉμ£Όμ‘°μ§ μΈν¬μ κΈ°λ₯μ μΈ λ³νμ κ΄ν μ¬μ€μ λ§μ΄ μλ €μ Έ μμ§ μλ€. λ
Ένμ λ°λ₯Έ μΈν¬μ λ
Ένκ° μΉμ£Όμ§νμ μ§νμ μ΄λ ν μ¬ν₯μ λΌμΉλκ°λ₯Ό μλ κ²μ μ€μνλ€. μΌμ¦ μνμμ nitric oxide (NO)λ μ‘°μ§ νκ΄΄μ κ΄μ¬νλ μΈμλ‘ μμ©νμ¬ μΉμ£Όμ§νμ μ§νμ κ΄μ¬νλ κ²μΌλ‘ μλ €μ Έ μλ€. λ°λΌμ μ΄ μ°κ΅¬λ μ¬λμ μΉμμμ λ°°μλ μΉμμ¬μ μμΈν¬λ₯Ό μ΄μ©νμ¬ μΈν¬μ λ
Ένμ λ°λ₯Έ NOμ μ΄μ ν©μ±ν¨μμΈ inducible nitric oxide synthase (iNOS)μ λ°νμ μμλ΄μΌλ‘μ¨ μΈν¬μ λ
Ένκ° μΉμ£Όμ§νμ μ§νμ λΌμΉλ μν₯μ λν΄ μμλ³΄κ³ μ νμλ€. 10μΈμ νμμ 55μΈμ νμμμ κ°κ° μ±μ·¨ν μΉμμμ λ°°μλ μΈν¬μ 10μΈμ νμμμ μ±μ·¨ν μΈν¬λ₯Ό κ³μμ μΈ κ³λλ°°μμ ν΅ν΄ μ»μ μ€νμ€ μ λ
Ένλ μΈν¬λ₯Ό ν¬ν¨νμ¬ μ΄ 3 μ’
λ₯μ μΉμμ¬μ μΈν¬λ₯Ό μ€νμ μ΄μ©νμλ€. Hot phenol-water extractionμ ν΅ν΄ μΆμΆλ Porphyromonas, gingivalis ATCC 33277 lipopolysaccharide (LPS)μ μ¬μ‘°ν© IFN-Ξ³λ₯Ό μΈν¬μ μ μ©μμΌ Griess assayλ₯Ό ν΅ν΄ 쑰건νλ λ°°μ§μμ NOλ₯Ό μΈ‘μ νμλ€. 20μΈμ 55μΈμ νμμμ μ±μ·¨λ μΉμ μ‘°μ§κ³Ό μ΄ 3 μ’
λ₯μ λ°°μλ μΈν¬μ NOS-II ν체λ₯Ό μ μ©μμΌ iNOS λ¨λ°±μ§ λ°νμ κ΄μ°°νμλ€. Total RNAλ₯Ό μΆμΆνμ¬ RT-PCRλ₯Ό ν΅ν΄ iNOS mRNAμ λ°νμ λΆμνμλ€. μΉμμ¬μ μμΈν¬μμ NOλ μλ°μ μΌλ‘ λ°μλμκ³ , μ΄λ¬ν λ°νμ μ μ μΈν¬λ³΄λ€ λ
Ένλ μΈν¬μμ κ°νμλ€. P, gingivalis LPSμ μ μ‘°ν© IFN-Ξ³λ μΉμμ¬μ μμΈν¬μμ NOμ λ°νμ μ¦κ°μμΌ°κ³ , μ΄λ¬ν λ°νμ μ μ μΈν¬λ³΄λ€ λ
Ένλ μΈν¬μμ κ°νμλ€. λ©΄μμ‘°μ§νν μΌμμμ iNOS λ¨λ°±μ§μ μ μ μ¬λκ³Ό λ
Ένλ μ¬λμ μΉμ μ‘°μ§ λͺ¨λμμ μΉμμ¬μ μμΈν¬μ μνΌμ κΈ°μ μΈ΅ μΈν¬μ μΌμ¦μΈν¬μμ λ°νλμμΌλ λ
Ένμ λ°λ₯Έ λ°νμ μ°¨μ΄λ₯Ό ꡬλ³ν μλ μμλ€. μΈν¬μ λ©΄μμΌμμμ iNOS λ¨λ°±μ§μ λ
Ένλ μΈν¬μμ κ°νκ² λ°νλμκ³ μ΄λ¬ν λ°νμ LPSμ IFN-Ξ³μ μν΄ κ°νλμλ€. LPSμ IFN-Ξ³μ μ‘°κ±΄μ΄ μ£Όμ΄μ§μ§ μμ μνμμ iNOS mRNAλ μ μ μΈν¬μμλ³΄λ€ λ
Ένλ μΈν¬μμ κ°νκ² λ°νλμλ€. μ΄λ¬ν κ²°κ³Όλ₯Ό ν΅ν΄ μΈν¬μ λ
Ένκ° NOμ iNOS λ°νμ μ¦κ°μν΄μΌλ‘μ μΉμ£Όμ§νμ μ§νμ μν₯μ λΌμΉ μ μμμ μμ¬νμλ€.This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea(03-PJ1-PG1-CH08-0001)
μΈκ°μ λ°μΉμ λ΄μμ 골μ λμ¬μμ νμ μΉμ μμ
μ΄ μ°κ΅¬λ μνλνΈλ₯Ό μ립νκΈ°λ₯Ό μνλ μ μ 건κ°μνκ° μνΈνλ©° ꡬκ°μμμνκ° μ’μ 14λͺ
νμ(λ¨μ:8λͺ
, μ¬μ:6λͺ
, νκ· λμ΄ : 44μΈ)μ 20κ°μ λ°μΉμ λ΄μ ν‘μμ± μ°¨νλ§(BioMesh. Sam Yang Corporation, Korea)κ³Ό ν¨κ» ννλλ 건쑰λμ’
골(dem-ineralized freezedried bone allografts, 250-500γ. Pacific Coast Tissue Bank, U.S.A.)κ³Ό μ΄μ’
골(Bovine-Bone, Bio-Oss 0.25-1.0 mm, Geistlich, Biomaterials and Osteohealth, Switzerland)μ 1:1(λΆνΌ)λ‘ νΌν©νμ¬ μ΄μν ν κ·Έ μΉμ μμμ κ΄μ°°νκ³ μ μ‘°μ§νμ λ° λ©΄μμ‘°μ§ννμ μΌλ‘ νκ°νμλ€. μ΄μ§μ¬κ° νλ½λλ κ²μ λ°©μ§νκΈ° μνμ¬ λ°μΉν ν 1κ°μμ΄ κ²½κ³Όλ νμ μ΄μμ¬μ μ°¨νλ§μ μμΉμμΌ°λ€. νλ³Έμ μμ μνμ¬ μ΄μμ μ μνν μ§ μ½ 6κ°μ νμ μνλνΈλ₯Ό μ립νκΈ° μ§μ μ립λΆμμμ trephine burλ‘ κ³¨μ μ±μ·¨νμλλ°, 20μ¦λ‘ μ€ 7μ¦λ‘μμ μνλνΈλ₯Ό μ립νκΈ° μ μ μ°¨νλ§μ΄ λ
ΈμΆλμλ€. μ°¨νλ§μ΄ λ
ΈμΆλμ§ μμ κ²μ λμ‘°κ΅°μΌλ‘, λ
ΈμΆλ κ²μ μ€νκ΅°μΌλ‘ μ€μ νμλ€. μ‘°μ§νμ μΈ κ΄μ°°μ μνμ¬ ν΅μμ μΈ λ°©λ²μ λ°λΌ νν νλ³Έμ μ μνμκ³ , alkaline phosphotase(ALP)ν μ΄μ©νμ¬ λ©΄μμ‘°μ§ννμ μΌμμ μνν ν 골 νμ± μνλ₯Ό νκ°νμ¬ λ€μκ³Ό κ°μ κ²°κ³Όλ₯Ό μ»μλ€. λ³Έ μ°κ΅¬μμλ λ°μΉμλ΄μμ 골μ λμ¬μμ ν λνλλ μΉμ ννλ₯Ό 5κ°μ§ ννλ‘ λΆλ₯ν μ μμλ€. Type I, IIμ IIIλ μλ‘μ΄ κ³¨ νμ±μ λνλ΄μ§ μμκ³ , λ©΄μμ‘°μ§ννμ κ²μ¬ μ ALP μμ± μ견μ λνλ΄μλ€. Type Vλ μλ‘μ΄ κ³¨ νμ±κ³Ό ALP μμ± μ견μ λνλ΄μμΌλ μΌμ¦, κ΄΄μ¬, κ²°ν©μ‘°μ§μ μ¦μ λ±μ μμλ€. Type IVμ Type Vμ μ°¨μ΄λ κ²°ν©μ‘°μ§μ μ¦μμ¬λΆλ‘ ꡬλΆλμλ€. λ§μ΄ λ
ΈμΆλμ§μμ μ¦λ‘λ€ μ€ 7 μ¦λ‘μμλ Type Vμ μΉμ ννλ₯Ό, 2μ¦λ‘μμλ Type IVμ μΉμ ννλ₯Ό λνλ΄μλ€. λ§μ΄ λ
ΈμΆλμλ μ¦λ‘μμλ Type I, II, IIIμ λ€μν μΉμ ννλ₯Ό λνλ΄μλ€. λ³Έ μ°κ΅¬κ²°κ³Ό, λ°μΉμ λ΄μ 골μ λμ¬μμ μ μνν ν μ°¨νλ§μ λ
ΈμΆ μ¬λΆκ° μ μ골 νμ±μ μ€μν μν₯μ λ―ΈμΉ κ²μΌλ‘ μ¬λ£λλ©°, λ³Έ μ°κ΅¬μμ λΆλ₯ν μΉμ ννκ° ν₯ν 골μ λμ¬μμ νμ κ²°κ³Ό λΆμμ νμ©λ μ μμ κ²μΌλ‘ μ¬λ£λλ€.This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare. Republic of Korea(03-PJ1-PG1-CH08-0001)
- β¦